Videos
Leukemia
Tanios Bekaii-Saab, MD, discusses the results from the phase III BEACON CRC study; investigators evaluated the efficacy and safety of triplet encorafenib, binimetinib, and cetuximab in patients with BRAF V600E–mutant metastatic colorectal cancer who previously received up to 2 lines of prior therapy.
Chronic Myeloid Leukemia
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ctDNA Refines Risk in Neoadjuvant-Resistant Breast Cancer
2
Promoting CAR T Access Focuses on Awareness, Capacity, and Economics
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Early AE Monitoring Is Key to Adjusting NALIRIFOX Dose in PDAC
5